Laos LuciDarax First Generic Launch: Opening a New Window of Accessible Treatment for Pancreatic Can

Pancreatic cancer, known as the “king of cancers,” has long been one of the hardest barriers to break through in clinical oncology. With a five-year relative survival rate of only 13.7%, combined with the long-standing lack of later-line treatment options, countless patients and their families have been left in the desperate situation of having no available treatment.

Recently, Lucius Pharmaceuticals (Laos) delivered major news: its generic version of Daraxonrasib (brand name LuciDarax) has officially obtained the drug registration certificate issued by the Food and Drug Administration of the Lao Ministry of Health, becoming the world’s first legally approved and marketed generic of this product.

This targeted drug for metastatic pancreatic cancer formally initiated its project and started pharmaceutical research in 2025, then completed a full set of quality compliance testing and finally obtained marketing approval. The entire process strictly followed international drug research and development standards. Unlike many generics on the market that are hastily launched, Lucius Pharmaceuticals established a complete quality management system for this product, and all indicators of the final product meet internationally accepted pharmaceutical quality standards. Stable supply for the global market was launched immediately after approval.

Compliant Production Capacity as the Foundation: Lao Pharmaceutical Company Joins the First Tier of High-End Targeted Drug Generic Manufacturing

Lucius Pharmaceuticals (Laos) Co., Ltd. is itself a compliant pharmaceutical enterprise formally approved and established by the Lao government. Its manufacturing site is located in Vientiane, the capital of Laos, with a total area of 210,000 square meters, where the Asia-Pacific No. 1 Smart Factory is located. Core equipment across the entire production line was imported from China, the United States, Germany, and other countries, with hardware configurations benchmarked against the standards of mainstream international pharmaceutical companies.

The company has already passed GMP (Good Manufacturing Practice) certification issued by the Lao Ministry of Health. In October 2023, the World Health Organization (WHO) also conducted a dedicated full-process system assessment of its factory, ultimately confirming that its production facilities and full-chain quality management system fully comply with WHO official standards. As of before the approval of Daraxonrasib, Lucius Pharmaceuticals had obtained marketing approvals for 54 anticancer drugs, had more than 200 generic varieties in production, and had an overall annual production capacity exceeding 1.5 billion tablets (capsules), demonstrating strong capability for large-scale stable supply.

Keeping Pace with the Originator: Filling the Key Accessibility Gap for the Pan-RAS Target

Just three months before the approval of this generic, namely on August 26, 2026, the originator product of Daraxonrasib had just received U.S. FDA approval for the clinical treatment of metastatic pancreatic cancer. As the world’s first approved pan-RAS targeted inhibitor, this drug directly broke the decades-long industry “curse” that the RAS target was “undruggable.” More than 90% of pancreatic cancer patients carry oncogenic mutations in the RAS gene family (predominantly KRAS mutations). Abnormal activation of the RAS signaling pathway is the core mechanism driving the occurrence and progression of pancreatic cancer. In the past, because the surface of the RAS protein lacked a suitable druggable binding pocket, related targeted therapies remained entirely absent.

After the originator drug was approved, its high pricing deterred the vast majority of patients from ordinary families. Relying on its mature generic drug research and development and registration system, Lucius Pharmaceuticals completed all pharmaceutical research, quality validation, and registration submission processes within only a few months after the originator product’s approval, ultimately achieving first generic approval. This directly and substantially lowered the cost of this breakthrough therapy, giving more ordinary patients an opportunity to access previously unreachable cutting-edge treatment options.

The successful launch of this Daraxonrasib generic also directly demonstrates that Lao domestic pharmaceutical companies already possess the generic research and development capability for high-end targeted anticancer drugs, further consolidating Laos’ industry positioning as an emerging global generic drug manufacturing base.

Precisely Matching the Needs of Patients with Metastatic Pancreatic Cancer

The core parameters of this generic, including the clinical indication population, dosage and administration, and safety warnings, are consistent with those of the originator drug. The specific indicated population is adult patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) whose disease has progressed after at least one prior systemic therapy, or who are not suitable for multi-agent combination systemic therapy.

Recommended Dosage

300 mg orally once daily. Swallow the tablet whole; do not chew, crush, or split it. It may be taken with or without food. Continue treatment until disease progression or unacceptable toxicity occurs.

Dose Adjustment

When used in combination with moderate CYP3A inhibitors, the dose should be reduced to 150 mg once daily; prophylactic and concomitant medications are clinically recommended to reduce the risk of skin adverse reactions.

Storage Requirements

For long-term storage, the ambient temperature should be controlled within the range of 20°C–25°C; short-term storage at 15°C–30°C is permitted.

Adverse Reactions

During treatment, close vigilance is required for several serious adverse reactions: skin and soft tissue toxicity (rash, pruritus, dry skin, etc.), stomatitis and various oral diseases, diarrhea, gastrointestinal perforation, interstitial lung disease/pneumonitis, and a clear risk of embryo-fetal toxicity.

Common adverse reactions with an incidence of ≥20% in clinical statistics include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

The global incidence of pancreatic cancer continues to rise, and the treatment needs of a large number of patients with metastatic pancreatic cancer remain insufficiently met. The launch of Lucius’ Daraxonrasib generic, which has undergone official formal registration and approval, provides patients worldwide with a compliant and affordable new treatment option and is expected to effectively improve the survival prognosis and quality of life of many patients with advanced disease. From the dilemma of the RAS target being “undruggable” to the launch of the originator drug and then the rapid arrival of the first generic, humanity’s steps toward conquering pancreatic cancer are being taken ever more firmly, one step at a time.